Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better

被引：0
|
作者：
Mannucci, Pier Mannuccio [1 ]
机构：
[1] Mangiagalli & Regina Elena Fdn, IRCCS Maggiore Hosp, Sci Direct, Milan, Italy
来源：
BLOOD TRANSFUSION | 2010年 / 8卷 / 04期
关键词：
VON-WILLEBRAND-FACTOR; PREVIOUSLY UNTREATED PATIENTS; INHIBITOR DEVELOPMENT; RISK-FACTORS; IN-VITRO; PRODUCTS; EPIDEMIOLOGY; ANTIBODIES; RELEVANCE; PROTECTS;
D O I：
10.2450/2010.0072.10
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：288 / 291
页数：4
相关论文
共 50 条
  • [31] ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates
    Peyvandi, Flora
    Mannucci, Pier M.
    Valsecchi, Carla
    Pontiggia, Silvia
    Farina, Claudio
    Retzios, Anastassios D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (10) : 895 - 898
  • [32] ADAMTS-13 content of plasma-derived factor VIII/von Willebrand factor concentrates
    Kingsland, Sarah
    Feldman, Peter
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : 667 - 668
  • [33] Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates
    Clifton, James G.
    Huang, Feilei
    Kovac, Spomenka
    Yang, Xinli
    Hixson, Douglas C.
    Josic, Djuro
    ELECTROPHORESIS, 2009, 30 (20) : 3636 - 3646
  • [34] Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro
    Astermark, J
    Voorberg, J
    Lenk, H
    Dimichele, D
    Shapiro, A
    Tjönnfjord, G
    Berntorp, E
    HAEMOPHILIA, 2003, 9 (05) : 567 - 572
  • [35] The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A
    Kevane, Barry
    O'Connell, Niamh
    TRANSFUSION AND APHERESIS SCIENCE, 2018, 57 (04) : 502 - 506
  • [36] Cellular Stress Induced by Plasma-Derived Factor VIII Products
    Brodde, Martin
    Mueller, Anja
    Kehrel, Beate
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2014, 41 (02) : 140 - 144
  • [37] Severe haemophilia A Plasma-derived FVIII concentrates are proven to generate fewer inhibitors
    Menke, Petra
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) : V - VII
  • [38] Case study immune-tolerance in haemophilia a using plasma-derived factor VIII concentrate
    Needham, J.
    Roy, A.
    Knight, S.
    Stebbings, Y.
    Rangarajan, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1133 - 1134
  • [39] Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review
    Iorio, A.
    Halimeh, S.
    Bidlingmaier, C.
    Ettingshausen, C. E.
    Gringeri, A.
    Holzhauer, S.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 (02) : 410 - 410
  • [40] Safety of recombinant and plasma-derived medicinals for the treatment of coagulopathies
    Radosevich, M
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (02) : 459 - +
12345